Voyager Therapeutics, Inc. (BMV:VYGR)

Market Cap	3.64B +20.4%
Revenue (ttm)	657.90M -45.5%
Net Income	-2.10B
EPS	-35.65
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Open	63.00
Previous Close	64.21
Day's Range	63.00 - 63.00
52-Week Range	58.00 - 94.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Voyager Therapeutics

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. The company also provides research program for the treatment of Huntington’s disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small mo...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 141
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: VYGR

Financial Performance

In 2025, Voyager Therapeutics's revenue was $40.37 million, a decrease of -49.53% compared to the previous year's $80.00 million. Losses were -$119.72 million, 84.2% more than in 2024.

Financial numbers in USD